Business Wire

AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes


AstraZeneca today launches Evinova, set to be a leading provider of digital health solutions to better meet the needs of healthcare professionals, regulators and patients. With long-term backing from AstraZeneca and strategic collaborations with Parexel and Fortrea, Evinova offers globally-scaled digital products and services to the life sciences and healthcare sector.

Evinova will prioritise bringing to market established and scaled digital technology solutions already being used globally by AstraZeneca to optimise clinical trial design and delivery. This will reduce the time and cost of developing new medicines, bring care closer to home for patients and reduce the burden on health systems. Evinova will also pursue opportunities in digital remote patient monitoring and digital therapeutics with a pipeline of digital innovations in these areas.

Drawing on AstraZeneca’s deep experience of developing novel therapeutics and with insights from thousands of patients and clinical researchers, Evinova will provide established technology solutions to pharma, biotech and CROs to support clinical research globally. The technologies have already been used in the successful delivery of multiple AstraZeneca-sponsored clinical trials in over 40 countries.

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “The future of medicine development can be accelerated with digital solutions. We believe Evinova’s combination of scientific expertise and track record in developing AI-enabled digital technologies at scale, provides a real opportunity to fundamentally improve patient care, drive healthcare transformation and reduce carbon emissions.”

Cristina Duran, President of Evinova, said: “We are excited to bring the portfolio of globally-scaled digital solutions developed to serve AstraZeneca’s drug development pipeline to the wider life sciences community. We believe this will help propel the sector forward in digital health, as we know healthcare professionals and regulators need digital solutions that work across pharma and support patients broadly. Coming from within the sector and with proven experience, Evinova will be uniquely placed to deliver science-based, evidence-led and human experience-driven solutions with the aim of improving patient experience and outcomes.”

Globally-leading CROs Parexel and Fortrea have entered into agreements to offer Evinova digital health solutions to their wide customer base. To accelerate industry adoption and sustain and expand the global reach of its digital products, Evinova is collaborating with Accenture and Amazon Web Services.

Evinova will combine clinical and regulatory experience gained at AstraZeneca with its deep expertise in digital technology spanning strategy and development, digital product development, data science and AI, user experience design and behavioural science. In addition to digital solutions, Evinova will offer custom scientific solutions, including remote patient monitoring and novel endpoint solutions, as well as trial design and consulting services.


Evinova products and solutions

Evinova has co-created with patients the Evinova drug development suite, a suite of digital solutions that aims to bring benefits to all participants – patients, healthcare professionals and researchers. The suite includes:

Evinova unified trial solution: A global GxP-validated solution for patients, clinical trial site staff and clinical trial sponsor staff to improve delivery of clinical trials. It enables the delivery of traditional, hybrid and decentralised clinical trials while enhancing the patient experience. The unified trial solution supports direct collection of primary and secondary endpoint data including novel digitally-enabled endpoints and connected medical devices and sensors at both the trial site and patient’s home. It also supports services for virtual visits including direct-to-patient delivery of medicines, telehealth, remote patient monitoring and human biological sample tracking. Patient interaction is available through an easy-to-use, engaging patient app available in more than 40 countries and 80 languages. Site interaction is available through a single-sign-on portal.

Evinova study design and planning: Uses AI and machine learning algorithms to aide clinical development and operations teams to design the optimal study considering critical design variables. Teams can design their study, get automatic costings and assess operational feasibility based on actual data from that indication at a country and site level. They can view historic data and forecast future trends. The module also contains models to estimate the study’s carbon footprint and impact on patient experience. Teams can accelerate decision-making through collaboration and scenario comparison capabilities.

Evinova portfolio management: Supports clinical programme and trial management, reporting and governance through transparent real-time insights and predictive analytics. It provides a complete picture of the portfolio across all phases and allows for tracking of clinical programmes and trials at global, regional, country and site level. It uses predictive algorithms to provide future key milestones, enabling study leaders to understand deviations from plans and supporting appropriate intervention.

Digital health

The application of digital health technologies is seen as a solution to reduce healthcare costs, while also helping to improve patient experience and outcomes​. Starting from around 6% of GDP in 2006-10, the combined public health and long-term care expenditure for OECD countries is projected to reach at least 9.5% in 2060. In BRIICS countries, spending ratios will also increase significantly, reaching around 10% of GDP by 2060 unless cost-containment policies are implemented.1 Based on 2018 healthcare spend information, McKinsey estimates that digital health interventions alone have the potential to save the US healthcare system nearly $500bn if fully adopted.2

Digital health is a large (+$900bn by 2032) and growing (13.6% CAGR 2022-2032) market. The market for R&D digital health and care delivery with remote patient monitoring, together make up approximately 60% of the total digital health market3. The remaining 40% consists of screening and diagnostics, wellness and disease prevention, supply of therapies and digital pharmacies.

Digital health technology and clinical research

A significant part of the cost and time of the drug development process is in the clinical trials, rather than designing molecules. However, they are vital to the drug development and approval process and critical in enabling access to innovative medicines. Studies estimate that it now costs up to $2bn to bring a new drug to market4 and according to one study the average length of time from the start of clinical testing to approval is 7.1 years.5 Across the industry, almost 80% of clinical trials fail to meet recruiting timelines6 and only 3-5% of eligible cancer patients join a clinical trial.7 Many groups, including marginalised racial and ethnic groups, women, and other populations are underrepresented in clinical trials.8

A recent AstraZeneca article published in Nature Medicine, lead author Cristina Duran, demonstrated that the implementation of digital health technology in clinical trials can improve the patient experience with accelerated timelines and reduced costs.9


AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit and follow the Company on Social Media @AstraZeneca.


Evinova is a health-tech business, accelerating the delivery of better health outcomes by propelling the life sciences sector forward in digital health, from the inside. Through our application of science-based expertise, evidence-led rigour, and human experience-driven insight, our digital solutions are deliberately designed so that everyone can reach better health outcomes together. Evinova is a health-tech business within the AstraZeneca Group.


For details on how to contact the Investor Relations Team, please clickhere. For Media contacts, click here.


  1. OECD. What future for health spending? Available at: Accessed November 2023.
  2. McKinsey & Company. Healthtech in the fast lane: What is fueling investor excitement? Available at: Accessed November 2023.
  3. Precedence Research​. Digital Health Market (By Component: Software, Hardware, and Services; By Technology: Telehealthcare [Telehealth and Telecare], mHealth [Apps and Wearables], Digital Health Systems [E-prescribing Systems and Electronic Health Records], and Health Analytics) - Global Market Size, Trends Analysis, Segment Forecasts, Regional Outlook 2023 – 2032. Available at: Accessed November 2023.
  4. Deloitte. Deloitte pharma study: Drop-off in returns on R&D investments. Available at: Accessed November 2023.
  5. Deloitte. Deloitte pharma study: Drop-off in returns on R&D investments. Available at: Accessed November 2023.
  6. Clinical Trials Arena. Clinical trial delays: America’s patient recruitment dilemma. Available at: Accessed November 2023.
  7. Baquet, C.R., Commiskey, P., Daniel Mullins, C., Mishra, S.I., Recruitment and participation in clinical trials: socio-demographic, rural/urban, and health care access predictors. Cancer Detect Prev. 2006;30(1):24-33. Available at: Accessed November 2023.
  8. Schwartz, A.L, Aslan, M., Morris, A.M., Halpern, S.D., Why diverse clinical trial participation matters. N Engl J Med 2023; 388:1252-1254. Available at: Accessed November 2023.
  9. Durán, C.O., Bonam, M., Björk, E. et al. Implementation of digital health technology in clinical trials: the 6R framework. Nat Med (2023). Available at: Accessed November 2023.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Brendan McEvoy

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

GWI Appoints New Chief Technology Officer, Nick Dearden6.12.2023 15:00:00 CET | Press release

GWI, the global consumer research platform, today announced that it has appointed Nick Dearden as Chief Technology Officer, based in its UK headquarters in London. Nick has over 25 years of experience in technology, with his grassroots as a developer. At GWI he will lead the engineering, IT, and security teams and will be responsible for the company's technology and data management strategy. His role is key to driving forward the company’s agenda to build technology that gives people clarity over their audience in the moment they need it. Nick’s role will focus on the ongoing innovation, scaling, and automation of processes that underpin access to data representative of nearly 3 billion people across 50+ markets. With simplification and ease of access to GWI data a key strategic driver, Nick will be responsible for identifying appropriate technology, such as AI, to define the technology strategy to achieve this. This will enable the company to automate and unlock powerful new features

AnyQuest Improves Citizen Developer Productivity by Launching Low-code Platform for Generative AI6.12.2023 15:00:00 CET | Press release

AnyQuest, the enterprise AI enabler, today announced the availability of AnyQuest PyAQ, an open-source low-code platform for cognitive applications. This press release features multimedia. View the full release here: Generative AI Cognitive apps can be deployed on AnyQuest and accessed from business applications and services with LLMs and plug-in tools. AnyQuest is an Enterprise AI enabler with an open-source, low-code development platform. (Graphic: Business Wire) Cognitive applications improve knowledge worker productivity by integrating generative AI with enterprise solutions for customer relationship management, marketing automation, enterprise resource planning, supply chain management, and many others. Unlike interactive GPT chatbots and copilots, cognitive applications can run entirely unattended. They do not sacrifice precision for speed and can run longer to process more data, use different types of larger AI models, or

Adani Green Energy Ranks Among Top 3 Global Solar PV Developer6.12.2023 13:55:00 CET | Press release

Adani Green Energy Limited (AGEL), India’s largest and one of the world’s leading renewable energy solutions partner, has attained the remarkable position of the second-largest global solar PV developer, in Mercom Capital Group's latest Annual Global Report. This press release features multimedia. View the full release here: Adani Green Energy Ranks Among Top 3 Global Solar PV Developer (Graphic: Business Wire) According to the report, AGEL's outstanding performance and contribution to the renewable energy landscape have earned it the prestigious second rank among the world's foremost solar PV developers. With an impressive total solar capacity of 18.1 GW encompassing operational, under-construction, and awarded (PPA-contracted) projects, AGEL solidifies its significant position in the global solar energy sector. With a total capacity of 41.3 GW, France-based TotalEnergies emerged at the top. Speaking on the ranking, Gautam Adan

COP28 Announcement Pushes for More Timber in Construction and More Sustainable Forestry6.12.2023 13:43:00 CET | Press release

The International Sustainable Forestry Coalition (ISFC), applauds the announcement made today at COP28 supporting the need to substantially increase the use of timber in construction as a vital decarbonisation strategy. The announcement was made at a COP Presidency event under the auspices of the Forests and Climate Leaders Partnership (FCLP) which is co-chaired by the United States Special Presidential Climate Envoy, John Kerry and the Minister of Lands and Natural Resources for Ghana, Samuel Jinapor. Today’s announcement said: A coalition of 17 countries – Commonwealth of Australia, Canada, Republic of Congo, Republic of Costa Rica, Republic of Fiji, Republic of Finland, Republic of France, Federal Republic of Germany, Republic of Ghana, Japan, Republic of Kenya, Republic of Korea, Kingdom of Norway, Islamic Republic of Pakistan, Kingdom of Sweden, United Kingdom of Great Britain and Northern Ireland, United States of America - have endorsed the following statement: Recognizing that

BYD and Latin American Energy Organization (OLADE) Form Strategic Partnership to Drive Electric Mobility6.12.2023 13:06:00 CET | Press release

BYD Ecuador (hereafter referred to as BYD) and the Latin American Energy Organization (OLADE) announced that an Interinstitutional Cooperation Agreement was formalized recently, with the aim of advancing the cause of electric mobility in Latin America and the Caribbean. This press release features multimedia. View the full release here: BYD and OLADE Form Strategic Partnership (Left: Executive Secretary of OLADE, Andrés Rebolledo Smitmans; Right: Country Manager of BYD Ecuador, Jorge Burbano) (Photo: Business Wire) OLADE, under the leadership of its Executive Secretary, Andrés Rebolledo Smitmans, and BYD, represented by Jorge Burbano, Country Manager of BYD Ecuador, have signed this agreement, solidifying their joint commitment to promoting electric vehicles and accelerating energy transitions in the region. Established in 1973, OLADE is a respected intergovernmental cooperation organization dedicated to fostering energy integra